Showing 6531-6540 of 8649 results for "".
- Verseon Presents New Efficacy Results on Oral DME Drug Candidate at ARVOhttps://modernod.com/news/verseon-presents-new-efficacy-results-on-oral-dme-drug-candidate-at-arvo/2480186/Verseon presented new efficacy results on its diabetic macular edema drug candidates at the Association for
- Avedro Announces $25 Million in Funding to Fuel Innovation and Commercial Growthhttps://modernod.com/news/avedro-announces-25-million-in-funding-to-fuel-innovation-and-commercial-growth/2480188/Avedro announced that it has secured $25 million in financing to invest in product development, clinical studies and commercial efforts, including expansion of sales and reimbursement support. “Avedro’s mission is to develop noninvasive corneal remodeling treatments that protect and improv
- Aldeyra Therapeutics Presents Dry Eye Disease Phase 2a Clinical Trial Results at ARVOhttps://modernod.com/news/aldeyra-therapeutics-presents-dry-eye-disease-phase-2a-clinical-trial-results-at-arvo/2480191/Aldeyra Therapeutics presented the results of a randomized, double-masked, parallel-group phase 2a dry eye disease clinical trial of topical ocular reproxalap at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting. The primary objective of the trial, to select a fo
- Call for Abstracts for Academy 2018 San Antonio Scientific Programhttps://modernod.com/news/call-for-abstracts-for-academy-2018-san-antonio-scientific-program/2480193/The Scientific Program Committee of the American Academy of Optometry invites the submission of abstracts for Academy 2018 San Antonio, to be held Wednesday, November 7 through Saturday, November 10. The Academy’s Scientific Program offers scientists, educators, and clinicians the opportuni
- J&J Vision Introduces Artificial-Intelligence Powered Virtual Assistant for Contact Lenseshttps://modernod.com/news/jj-vision-introduces-artificial-intelligence-powered-virtual-assistant-for-contact-lenses/2480195/Johnson & Johnson Vision introduced Andy, a virtual assistant chatbot powered by artificial intelligence (AI). Andy is designed to help guide U.S. consumers throughout their Acuvue brand contact lens journey – from those considering contact lenses for the first time to long-term wearers. The
- Bausch + Lomb Will Present Scientific and Clinical Research During ARVO Meeinghttps://modernod.com/news/bausch-lomb-will-present-scientific-and-clinical-research-during-arvo-meeing/2480199/Bausch + Lomb announced that nearly a dozen scientific posters will address the results of studies featuring several of the company’s current product offerings and pipeline programs in its Consumer Health Care, Pharmaceuticals and Surgical businesses during the Association for Research in Vision
- ThromboGenics Initiates Phase 2 Clinical Study Evaluating Anti-PlGF in Combination With Anti-VEGF for Treatment of DMEhttps://modernod.com/news/thrombogenics-initiates-phase-2-clinical-study-evaluating-anti-plgf-in-combination-with-anti-vegf-for-treatment-of-dme/2480200/ThromboGenics announced that it has successfully enrolled the first patient in a phase 2 active-controlled, masked, multicenter study to evaluate the efficacy and safety of THR-317 administered in combination with ranibizumab (Lucentis, Novartis), for the treatment of DME (NCT03499223). TH
- Johnson & Johnson Vision Highlights New Data at 2018 ARVO Annual Meetinghttps://modernod.com/news/johnson-johnson-vision-highlights-new-data-at-2018-arvo-annual-meeting/2480201/Johnson & Johnson Vision announced that a suite of new research from its eye health portfolio will be presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Honolulu, Hawaii from April 29 to M
- Allergan Presents Data at the ARVO Annual Meeting in Honoluluhttps://modernod.com/news/allergan-presents-data-at-the-arvo-annual-meeting-in-honolulu/2480202/Allergan announced that 19 posters on their eye care offerings will be presented at this year’s ARVO meeting in Hawaii. These presentations will cover a variety of topics in various subspecialties, including ocular surface, glaucoma, and retina. Retina Post
- EyePrint Prosthetics Announces Clinical Outcomes Achieved With EyePrintPROhttps://modernod.com/news/eyeprint-prosthetics-announces-clinical-outcomes-achieved-with-eyeprintpro/2480203/EyePrint Prosthetics, a company dedicated to restoring vision to patients who have complex corneal irregularities, announced the clinical outcomes that have been achieved since the EyePrintPRO lens was FDA-cleared 2 y